Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
November 12, 2024 4:24 PM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $362.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "When has three patients worth of data ever been the 'be all and end all'? Context matters, and while this MariTide data... More
Barclays Reiterates Equalweight Rating on Amgen (AMGN)
November 12, 2024 4:23 PM ESTBarclays analyst Carter Gould reiterated an Equalweight rating and $315.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We reviewed the supplemental MariTide (AMG133) phase 1 data, highlighted by (1) BMD loss (as measured by DEXA scan across femur and hip) at higher doses (420mg), and (2) notable heart rate excursions (25bpm at the 280mg dose). While far from... More
Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'
November 12, 2024 3:44 PM ESTJefferies analyst Michael Yee reiterated a Buy rating and $380.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We reviewed public data from Phase I AMG-133 showing add'l measurements of BMD (bone density) from obesity pts - which could be interpreted... More
Amgen (AMGN) Quickly Falls to Low, Down Over 4% on Obesity Data Concerns
November 12, 2024 2:19 PM EST(Updated - November 12, 2024 2:30 PM EST)
(Updated - November 12, 2024 2:21 PM EST)
Amgen (NASDAQ: AMGN) Quickly Falls to Low, Down Over 4%
Weakness appears to be related to concerns about its developmental weight loss... MoreAmgen (AMGN): Tezspire Met Both Co-primary Endpoints In Phase 3 Trial For Chronic Rhinosinusitis With Nasal Polyps
November 8, 2024 7:06 AM ESTAmgen (NASDAQ: AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability of TEZSPIRE in the trial were consistent with the known profile of the medicine.
WAYPOINT was a randomized, double-blind, placebo-controlled trial evaluating the... More
